|   Sulfabenzamide structure | Common Name | Sulfabenzamide | ||
|---|---|---|---|---|
| CAS Number | 127-71-9 | Molecular Weight | 276.311 | |
| Density | 1.4±0.1 g/cm3 | Boiling Point | N/A | |
| Molecular Formula | C13H12N2O3S | Melting Point | 180-184 °C | |
| MSDS | Chinese USA | Flash Point | N/A | |
| Use of SulfabenzamideSulfabenzamide is a intermediate in the synthesis of organic and pharmaceutical. | 
| Name | Sulfabenzamide | 
|---|---|
| Synonym | More Synonyms | 
| Description | Sulfabenzamide is a intermediate in the synthesis of organic and pharmaceutical. | 
|---|---|
| Related Catalog | 
| Density | 1.4±0.1 g/cm3 | 
|---|---|
| Melting Point | 180-184 °C | 
| Molecular Formula | C13H12N2O3S | 
| Molecular Weight | 276.311 | 
| Exact Mass | 276.056854 | 
| PSA | 97.64000 | 
| LogP | 1.19 | 
| Index of Refraction | 1.636 | 
| Storage condition | 2-8°C | 
| Water Solubility | 0.3 g/L (20 ºC) | 
| CHEMICAL IDENTIFICATION
 
 
 
 
 
 
 
 
 HEALTH HAZARD DATAACUTE TOXICITY DATA
 
 
 
 
 
 | 
| Personal Protective Equipment | Eyeshields;Gloves;type N95 (US);type P1 (EN143) respirator filter | 
|---|---|
| Hazard Codes | N | 
| Safety Phrases | S22-S24/25 | 
| RIDADR | 3249 | 
| WGK Germany | 3 | 
| RTECS | CV5802500 | 
| Packaging Group | III | 
| Hazard Class | 6.1(b) | 
| HS Code | 2934999090 | 
| HS Code | 2924299090 | 
|---|---|
| Summary | 2924299090. other cyclic amides (including cyclic carbamates) and their derivatives; salts thereof. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:30.0% | 
| Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps). J. Sci. Ind. Res. 65(10) , 808, (2006) Drug-induced liver injury (DILI) is a significant concern in drug development due to the poor concordance between preclinical and clinical findings of liver toxicity. We hypothesized that the DILI typ... | |
| Developing structure-activity relationships for the prediction of hepatotoxicity. Chem. Res. Toxicol. 23 , 1215-22, (2010) Drug-induced liver injury is a major issue of concern and has led to the withdrawal of a significant number of marketed drugs. An understanding of structure-activity relationships (SARs) of chemicals ... | |
| A predictive ligand-based Bayesian model for human drug-induced liver injury. Drug Metab. Dispos. 38 , 2302-8, (2010) Drug-induced liver injury (DILI) is one of the most important reasons for drug development failure at both preapproval and postapproval stages. There has been increased interest in developing predicti... | 
| Benzamide, N-[(4-aminophenyl)sulfonyl]- | 
| N-[(4-Aminophenyl)sulfonyl]benzamide | 
| N-(4-Aminobenzenesulfonyl)benzamide | 
| 4-Amino-N-benzoylbenzenesulfonamide | 
| N-Benzoylsulfanilamide | 
| Sulfabenzamide | 
| N-(4-aminophenyl)sulfonylbenzamide | 
| MFCD00044890 | 
| Sulfabenzamide(SB) | 
| Sultrin | 
| EINECS 204-859-4 |